Copper deficiency myeloneuropathy …

Neeraj Kumar MD

Peripheral Neuropathies

Updated 06.19.2024
Released 09.15.2009
Expires For CME 06.19.2027

Copper deficiency myeloneuropathy

Author: Neeraj Kumar MD

See Contributor Disclosures

Editor: Louis H Weimer MD

Copper deficiency myeloneuropathy

In This Article

Quick Link

Introduction

Overview

The commonest neurologic manifestation of acquired copper deficiency is that of a myelopathy. A peripheral neuropathy of variable severity is commonly associated with the myelopathy. Anemia and neutropenia are well-recognized hematologic manifestations of acquired copper deficiency. Copper deficiency myeloneuropathy may be present without hematological manifestations. The commonly identified causes of acquired copper deficiency include a prior history of gastric surgery, excessive zinc ingestion, and malabsorption. Copper and vitamin B12 deficiency may coexist. Estimation of serum copper levels should be a part of the work-up in patients with a myelopathy or myeloneuropathy, particularly in patients with a high risk of developing copper deficiency. In this article, the author discusses the topic of acquired copper deficiency, with a special emphasis on its neurologic manifestations.

Key points

	• The commonest neurologic manifestation of acquired copper deficiency is that of a myelopathy. A peripheral neuropathy of variable severity is commonly associated with the myelopathy.
	• Anemia and neutropenia are well-recognized hematologic manifestations of acquired copper deficiency. Copper deficiency myeloneuropathy may be present without hematological manifestations.
	• The commonly identified causes of acquired copper deficiency include a prior history of gastric surgery, excessive zinc ingestion, and malabsorption.
	• Copper and vitamin B12 deficiency may coexist.
	• Estimation of serum copper levels should be a part of the work-up in patients with a myelopathy or myeloneuropathy, particularly in patients with a high risk of developing copper deficiency.
	• A low copper level can also be seen in Wilson disease, a disorder of copper toxicity, or in carriers of the Wilson disease gene. In Wilson disease, copper deposited in tissues and copper excreted in urine is increased.

Historical note and terminology

Copper deficiency-associated myelopathy has been well described in various animal species. Often seen in ruminants, it has been called swayback or enzootic ataxia. Only in more recent years have the neurologic manifestations of acquired copper deficiency in humans been recognized (79; 84; 23; 80; 78; 31; 55; 59; 49; 52; 56; 53; 46; 22; 58; 82; 98; 14; 46; 85; 86; 97; 101; 39; 88; 29; 41; 70; 19; 20; 32; 68; 87; 103; 01; 36; 96; 34; 45; 17). The neurologic syndrome due to acquired copper deficiency may be present without the hematological manifestations (55; 59; 49; 52; 56; 46). Copper deficiency since birth is seen in Menkes disease. Comparative neuropathological studies have shown similarities between Menkes disease and swayback.

Clinical manifestations

Presentation and course

Neurologic manifestations. The most common neurologic manifestation of acquired copper deficiency is that of a myelopathy or myeloneuropathy that resembles the subacute combined degeneration seen with vitamin B12 deficiency (84; 31; 22; 55; 59; 49; 52; 56; 53; 46; 58; 82; 14; 46; 78; 86; 101; 85; 88; 41; 70; 19; 20; 32; 68; 87; 01; 36; 96; 34; 45; 17; 74). Copper deficiency myeloneuropathy may have a subacute onset. It presents with a spastic gait and prominent sensory ataxia. The sensory ataxia is primarily due to dorsal column dysfunction. Clinical or electrophysiological evidence of an associated axonal peripheral neuropathy is common (46; 19). Mixed demyelination and axonal loss have been reported. EMG evidence of a polyradiculopathy has also been described. Myopathic potentials may be seen. A wrist drop or foot drop may be present (49; 52; 56; 25; 03). Peripheral neuropathy without myelopathy; CNS or PNS demyelination (including an acute inflammatory demyelinating polyneuropathy like presentation); myopathy with myelopathy; autonomic neuropathy (without associated symptoms) and myelopathy; optic neuropathy with or without myelopathy; optic neuritis with peripheral neuropathy; a non-length-dependent distribution of sensory manifestations with face and trunk involvement and electrodiagnostic or imaging studies suggestive of a sensory ganglionopathy (sensory neuronopathy); quadriparesis with MRI evidence of brainstem disease; cerebellar ataxia with a myeloneuropathy; and cognitive impairment with myelopathy have also been described in case reports in association with copper deficiency, but the significance of some of these reported associations need further study (79; 23; 80; 58; 98; 85; 88; 70; 103; 76; 45; 40; 81; 07; 90; 03). An optic neuropathy may coexist (102). Visual loss can be sudden in onset and rapidly progressive (68; 34; 45). The initial presentation of a peripheral neuropathy may be followed by a myeloneuropathy (14). In some reports, adequate details of the neurologic findings are not provided, making it difficult to ascertain if a myeloneuropathy or neuropathy was the predominant reason for the neurologic symptoms. Also reported is progressive, asymmetric weakness or electrodiagnostic evidence of denervation, suggestive of lower motor neuron disease (97; 70; 06). In an additional patient, copper deficiency myelopathy had initially been misdiagnosed as postpolio syndrome (86). In some patients a pure or predominantly motor neuropathy is associated with the myelopathy (46). Of interest is a report that noted missense mutations in ATP7A (Menkes disease gene), which can cause an X-linked distal motor neuropathy (42). These patients don’t have overt signs of systemic copper deficiency. The ATP7A copper transporter may have an important role in motor neuron maintenance and function. One patient with a copper deficiency-related myelo-optico-neuropathy reported severe hyposmia and hypogeusia (88).

The myelopathy of copper deficiency closely mimics the subacute combined degeneration of vitamin B12 deficiency (56). Copper and vitamin B12 deficiency may coexist (49; 52; 56; 98; 14; 95). A prior history of vitamin B12 deficiency may be present, particularly in patients with a prior history of gastric surgery (49; 14; 46). Patients may be given vitamin B12 despite normal serum vitamin B12 levels (84). Coexisting iron deficiency may also be present (56; 14). Continued neurologic deterioration in patients with a history of vitamin B12 deficiency-related myelopathy who have a normal B12 level on B12 replacement should be evaluated for copper deficiency.

Clioquinol was initially developed as a tropical and intestinal antiseptic. It was commonly used as an over-the-counter antiparasitic agent. Its use resulted in over 10,000 cases of myelo-optico-neuropathy (SMON) in Japan in the 1960s to 1970s. Severely affected patients with SMON developed a green, hairy tongue due to green-black deposits of an iron chelate of clioquinol. Clioquinol was then withdrawn from the market. The precise mechanism of clioquinol-induced myelopathy has not been established. The myelo-optico-neuropathy seen with copper deficiency is similar to that seen due to the copper chelator clioquinol; it has been speculated that copper deficiency may have been the mechanism of clioquinol toxicity (57; 88; 83).

Hematological manifestations. The hematological hallmark of copper deficiency is anemia and neutropenia (23; 53; 29; 62; 67). Lymphopenia or thrombocytopenia with resulting pancytopenia is relatively rare. The anemia may be microcytic, macrocytic, or normocytic. Typical bone marrow findings include a left shift in granulocytic and erythroid maturation with cytoplasmic vacuolization in erythroid and myeloid precursors and the presence of ringed sideroblasts (79; 98; 29; 26; 65). Erythroid hyperplasia with decreased myeloid to erythroid ratio and dyserythropoiesis including megaloblastic changes may be seen. Hemosiderin-containing plasma cells may be present. Patients may be given a diagnosis of sideroblastic anemia or myelodysplastic syndrome or aplastic anemia. Patients with myelodysplastic syndrome typically do not have myeloid lineage vacuolization, abnormal nuclear lobulation of erythroid and myeloid precursors, or dysmegakaryopoiesis (62). The neurologic syndrome due to acquired copper deficiency may be present without the more commonly reported hematological manifestations.

Hepatic manifestations. The metabolic fates of copper and iron are closely linked through ceruloplasmin and hephaestin. Ceruloplasmin is the principal copper-carrying protein and decreases in acquired copper deficiency. Congenital absence of ceruloplasmin (aceruloplasminemia) results in tissue iron overload. Acquired copper deficiency may result in impaired iron utilization and abnormalities on blood iron studies (91). Hepatic iron overload or cirrhosis may occur and is likely mediated by hypoceruloplasminemia.

Prognosis and complications

Response of the hematological parameters (including bone marrow findings) is prompt and often complete (23; 22; 98; 46). Hematological recovery may be accompanied by reticulocytosis. Recovery of neurologic signs and symptoms is variable. Improvement in neurologic symptoms is generally absent though progression is typically halted (80; 22; 98; 46; 41). Improvement when present is often subjective and involves sensory symptoms (84; 80; 46). There are reports of definite improvement in the neurologic deficits, nerve conduction studies, evoked potential studies, autonomic function, and MRI signal change with normalization of serum copper (79; 31; 82; 46; 85; 101; 70). Also reported is stabilization or improvement in some patients who presented with clinical or electrodiagnostic evidence of lower motor neuron disease (97). A relapse in the copper-deficient state may not be necessarily accompanied by neurologic deterioration (80). Further, the initial response to copper replacement may not be sustained over time, and a relapse may occur during continued oral treatment (78).

Biological basis

Copper is a component of metalloenzymes that have a critical role in the structure and function of the nervous system. Copper functions as a prosthetic group in a number of enzymes that act as oxidases and permits electron transfer in key enzymatic pathways. These enzymes include cytochrome-c-oxidase for electron transport and oxidative phosphorylation in the mitochondrial respiratory chain, copper/zinc superoxide dismutase for antioxidant defense, tyrosinase for melanin synthesis, dopamine beta-hydroxylase for catecholamine biosynthesis, lysyl oxidase for crosslinking of collagen and elastin (in connective tissue, bones, and vasculature), peptidylglycine alpha-amidating monooxygenase for neuropeptide and peptide hormone processing, and ceruloplasmin (ferroxidase I) for brain iron homeostasis. Hephaestin is a multicopper ferroxidase necessary for iron egress from intestinal enterocytes into the circulation and is an important link between copper and iron metabolism in mammals. Reduction in cytochrome c oxidase activity may be the likely basis for neurologic dysfunction associated with the copper-deficient state. The similarities between copper deficiency myelopathy and subacute combined degeneration due to vitamin B12 deficiency have led to the speculation that dysfunction of the methylation cycle and associated failure of myelin maintenance may be the basis of neurologic derangement in copper deficiency (99).

Impaired erythroid and myeloid maturation and reduced erythrocyte and neutrophil life spans are the likely reasons for the anemia and neutropenia. Copper-containing enzymes likely play a role in cell differentiation and proliferation in the bone marrow. Decreased activity of copper/zinc superoxide dismutase may accelerate cell membrane defects and shorten the survival time of erythrocytes. Copper deficiency may also impair effective iron utilization and interfere with erythropoiesis.

Etiology and pathogenesis

Though rare, acquired copper deficiency has been well documented in humans (92; 04). The presence of multiple causes can increase the chances of development of a clinically significant deficiency state (88; 102). Coexistence of copper deficiency myelopathy with advanced degenerative cervical spondylosis can pose a management challenge (72). The commonest identified likely cause of copper deficiency in reported patients with a copper deficiency myelopathy has been a prior history of gastric surgery (for peptic ulcer disease, bariatric surgery, or intestinal resection) (84; 23; 59; 49; 52; 56; 14; 46; 78; 97; 39; 88; 29; 34; 08; 18; 102; 21; 43; 38; 66). A prior history of gastric surgery is present in nearly half the reported cases of copper deficiency myelopathy (99; 36). The duration between gastric surgery and onset of neurologic symptoms may range from less than a year to 46 years (46; 78; 36; 38). In a report, a posterolateral myelopathy related to copper or vitamin B12 deficiency was the commonest neurologic complication seen following bariatric surgery (39). One study noted copper deficiency in 15.4% of patients following Roux-en-Y gastric bypass surgery (13).

Excessive zinc ingestion is a well-recognized cause of copper deficiency (55; 82; 98; 86; 97; 88; 70; 32; 87; 01; 11; 104; 27). Zinc causes an upregulation of metallothionein production in the enterocytes. Metallothionein is an intracellular ligand, and copper has a higher affinity for metallothionein than zinc. Copper displaces zinc from metallothionein, binds preferentially to the metallothionein, remains in the enterocytes, and is lost in the stools as the intestinal cells are sloughed off. One report suggests that zinc toxicity may be causative (104). Zinc is believed to be essential for optimal functioning of the immune system and has been empirically used for this purpose, often in high doses, and at times with deleterious consequences; this has been a point of particular importance during the COVID-19 pandemic (16). In addition to the common use of zinc in the prevention or treatment of common colds and sinusitis, zinc therapy has been used for conditions like acrodermatitis enteropathica, hidradenitis suppurativa, treatment of decubitus ulcers, sickle cell disease, celiac disease, glucagonoma, hepatic encephalopathy, psychosis, memory impairment, diarrhea, myoclonic epilepsy, macular degeneration, and acne. Parenteral zinc overloading during chronic hemodialysis or oral zinc supplementation in patients on hemodialysis has also been associated with copper deficiency with or without a myelopathy (101; 71). Unusual, but not uncommon, sources of excess zinc have included patients who consumed excessive amounts of denture cream for long periods and very rarely patients swallowing zinc-containing coins (30; 98; 70; 32; 87; 11; 102; 37). One report suggests that some patients with copper deficiency of indeterminate cause may have had denture cream use as a possible source that was not specifically looked for (32). In this report, the use of denture fixatives in 11 patients with myeloneuropathy–hypocupremia–hyperzincemia was evaluated, and the study noted a history of poorly fitting dentures and application of excessive amounts of denture adhesives in all. Even in the absence of excess use or ingestion, denture cream use may be an unintentional zinc ingestion source that may compromise copper balance in patients with an additional cause for copper deficiency (88). Overtreatment of Wilson disease with zinc has rarely been reported to cause copper deficiency-related hematologic and neurologic manifestations (15; 12; 64; 100). Rarely, copper deficiency may be seen in Wilson disease in the absence of zinc toxicity; malabsorption or reduced oral intake due to dysphagia may be responsible (93). An elevated serum zinc level in the absence of obvious exogenous zinc ingestion has been reported, but these reports antedate the recognition of excess use of zinc-containing denture creams as a potential source of hypocupremia-related myelopathy (79; 80; 31; 22; 52; 98; 46). Urinary zinc excretion correlated poorly with serum zinc levels. A report describes the existence of myelopathy among zinc-smelter workers in upper Silesia during the late 19th century (61).

Copper is widely distributed in foods. The bioavailability of copper from diet is approximately 70%. Copper is probably absorbed from the stomach and proximal intestines. Bile is the major pathway for copper excretion. Excretion of copper into the gastrointestinal tract is the major pathway that regulates copper homeostasis and prevents deficiency or toxicity. Because of copper’s ubiquitous distribution and low daily requirement, acquired dietary copper deficiency is rare. Overt copper deficiency is not a public health concern for most population groups. Under certain circumstances, clinical conditions may predispose individuals to the risk of copper deficiency. Copper deficiency may occur in premature infants or low-birthweight infants and in malnourished infants (47). Other causes of copper deficiency include nephrotic syndrome, glomerulonephritis, a ketogenic diet, alcoholism, and enteropathies associated with malabsorption like cystic fibrosis, sprue, systemic sclerosis, Crohn disease, and celiac disease (58; 33; 19; 28; 96; 10; 24; 35). Copper deficiency myelopathy has been reported in celiac disease without gastrointestinal manifestations (20; 28; 09). Bacterial overgrowth has also been implicated as a cause of copper deficiency in a patient with a prior history of gastric surgery (88). Copper deficiency in celiac disease or other causes of malabsorption may be accompanied by deficiency of zinc, vitamin B12, vitamin A, vitamin D, vitamin E, and iron (33; 02).

Copper deficiency may be a complication of prolonged total parenteral nutrition, particularly so when copper supplementation in TPN is withheld due of cholestasis. Enteral feeding with inadequate copper has also been known to result in copper deficiency. Treatment (self-treatment) with the copper-chelating agent tetrathiomolybdate (obtained by placing an order on the Internet) has been reported to cause copper deficiency (60). Tetrathiomolybdate has anti-angiogenic properties and has been proposed in the treatment of metastatic cancers. Therapy with proton pump inhibitors has been suspected as a possible cause for copper deficiency in some patients (77). Hypocupremic myelopathy has rarely been noted in the postpartum period (73).

At times the cause of the copper deficiency is unclear. A review of 55 case reports of copper deficiency myelopathy noted no identified cause in 20% of cases (36). In two patients with idiopathic hypocupremia and myelopathy, the copper content in the colonic mucosa was increased (49). In one of these patients a search for mutations in the Menkes gene (ATP7A) was negative (46). Emerging knowledge about copper transport may help clarify the etiology of idiopathic hypocupremia (94; 05). It is prudent to not attribute a low serum copper to copper deficiency in the absence of a known cause for copper deficiency.

Information on the pathology of copper deficiency myelopathy comes from animal studies. The typical distribution of lesions in the spinal cord is greater involvement of the cervical cord with less severe changes in the thoracic and lumbar segments (75). Wallerian degeneration and demyelination with microcavitation of the white matter of the spinal cord may be seen. A postmortem report of copper deficiency myelopathy showed the expected degeneration involving the dorsal and lateral columns (01). In two additional reports, concomitant folate deficiency and selenium deficiency were present (69; 44). Small inflammatory infiltrates have been seen on nerve biopsy in patients with a sensory predominant peripheral neuropathy in copper deficiency, but these are of doubtful clinical significance (90).

Diagnostic workup

Laboratory indicators of copper deficiency include reduced serum copper or ceruloplasmin and a reduction in urinary copper excretion. Urinary copper declines only when dietary copper is very low (92). These parameters may not be sensitive to marginal copper status. Serum copper may be inadequate for assessing total body copper stores, and activity of copper enzymes like erythrocyte superoxide dismutase and platelet or leukocyte cytochrome c oxidase may be a better indicator of metabolically active copper stores. Serum or urinary zinc elevation may be seen in the absence of exogenous zinc ingestion. Changes in serum copper usually parallel the ceruloplasmin concentration. Ceruloplasmin is an acute-phase reactant, and the rise in ceruloplasmin is probably responsible for the increase in serum copper seen in a variety of conditions like pregnancy, oral contraceptive use, liver disease, malignancy, hematologic disease, myocardial infections, smoking, diabetes, uremia, and various inflammatory and infectious diseases. Copper deficiency could be masked under these conditions. A low serum copper or ceruloplasmin can be seen in Wilson disease or the Wilson disease heterozygote state. In Wilson disease, there is tissue copper overload, and urinary copper excretion is increased. A urine 24-hour copper excretion is useful in evaluating a low serum copper of indeterminate etiology because it is almost always elevated in Wilson disease and, to a lesser extent, in some carriers of the Wilson disease gene (ATP7B). Serum ceruloplasmin is absent in aceruloplasminemia. Hence, the laboratory detection of a low serum copper does not imply copper deficiency (47). Laboratory evaluation may also show anemia or leukopenia or, rarely, thrombocytopenia or pancytopenia anemia.

MRI and somatosensory-evoked potential studies provide additional evidence of posterior column dysfunction. The commonest abnormality on the spine MRI is increased T2 signal involving the dorsal column; rarely, signal change involving the lateral column may be seen (56; 46; 46; 88; 19; 45). This pattern is similar to the spine MRI changes seen in patients with vitamin B12 deficiency. The cervical cord is most commonly involved, and contrast enhancement typically is not present. In a review of 55 case reports of copper deficiency myelopathy, spine MRI abnormality was seen in 47% of cases (36). Also reported was accompanying signal change involving the pyramidal tract in the brainstem (45). Dorsal column signal change may also reflect a sensory neuronopathy (07). Nonspecific or confluent areas of increased signal involving the subcortical or periventricular white matter have been reported but are of uncertain significance (79; 80; 56; 88; 70). Somatosensory-evoked potential and nerve conduction studies suggest impaired central conduction and varying degrees of peripheral neuropathy (55; 86; 88; 19). Other reported electrophysiological abnormalities noted in patients with copper deficiency and neurologic manifestations include prolonged visual-evoked potentials and impaired central conduction on transcranial magnetic stimulation (79; 84; 80; 88).

Management

Supportive measures are discussed in Peripheral neuropathies: supportive measures and rehabilitation.

There have been no studies that address the most appropriate dose, duration, and route of copper supplementation. In patients with hematological manifestations of copper deficiency in whom excess zinc ingestion is present, stopping zinc supplementation may suffice, and no additional copper supplementation may be required (98). Copper may be given in addition to stopping zinc supplementation (97). Commonly used copper salts include copper gluconate, copper sulphate, and copper chloride. In our practice, we give 8 mg of elemental copper orally for a week, 6 mg for the second week, 4 mg for the third week, and 2 mg thereafter. Periodic assessment of serum copper is essential to determine adequacy of replacement and to decide on the most appropriate long-term administration strategy. Because of the need for long-term replacement, parenteral therapy is not preferred and generally not required, even in cases with a suspected absorption defect. At times, prolonged oral therapy may not result in improvement and parenteral therapy may be required. Some copper supplements may not be adequately absorbed when administered through a jejunostomy tube, necessitating parenteral therapy. If required, 2 mg of elemental copper may be administered intravenously daily for 5 days and periodically thereafter. Initial parenteral administration followed by oral therapy has also been used (23; 82; 14). Rarely reversal of gastric bypass may be required to treat copper deficiency (89). In some cases, low serum copper levels persist despite aggressive supplementation (including parenteral administration); the reason for this is unknown but may relate to copper-related genetic polymorphisms (06).

In one report, overtreatment of copper deficiency resulted in hepatic copper overload with cirrhosis that required liver transplantation; genetic testing for ATP7B mutations was negative (63).

References

01: Afrin LB. Fatal copper deficiency from excessive use of zinc-based denture adhesive. Am J Med Sci 2010;340(2):164-8. PMID 20555248
02: AlHassany AA. Night blindness due to vitamin A deficiency associated with copper deficiency myelopathy secondary to bowel bypass surgery. BMJ Case Rep 2014;2014. PMID 24781845
03: Al-Tabbaa MM, Horvath E. Idiopathic copper deficiency induced myeloneuropathy. Cureus 2021;13(9):e18130. PMID 34692339
04: Altarelli M, Ben-Hamouda N, Schneider A, Berger MM. Copper deficiency: causes, manifestations, and treatment. Nutr Clin Pract 2019;34:504-13. PMID 31209935
05: Bach JP, Kumar N, Depboylu C, et al. Copper deficiency associated with severe neurological disorder--a genetic work-up of possible mutations in copper transport proteins. J Neurol Sci 2010;291(1-2):95-7. PMID 20149918
06: Benkirane A, Warlop T, Ivanoiu A, et al. Case report: motor neuron disease phenotype associated with symptomatic copper deficiency: challenging diagnosis and treatment. Front Neurol 2022;13:1063803. PMID 36686537
07: Birnbaum J, Lalji A, Piccione EA, Izbudak I. Magnetic resonance imaging of the spinal cord in the evaluation of 3 patients with sensory neuronopathies: diagnostic assessment, indications of treatment response, and impact of autoimmunity: a case report. Medicine (Baltimore) 2017;96(49):e8483. PMID 29245216
08: Btaiche IF, Yeh AY, Wu IJ, Khalidi N. Neurologic dysfunction and pancytopenia secondary to acquired copper deficiency following duodenal switch: case report and review of the literature. Nutr Clin Pract 2011;26(5):583-92. PMID 21947641
09: Cavallieri F, Fini N, Contardi S, Fiorini M, Corradini E, Valzania F. Subacute copper-deficiency myelopathy in a patient with occult celiac disease. J Spinal Cord Med 2017;40(4):489-91. PMID 27841075
10: Chin A. Copper deficiency anemia and neutropenia due to ketogenic diet. Pediatrics 2018;141(5):e20173286. PMID 29695584
11: Doherty K, Connor M, Cruickshank R. Zinc-containing denture adhesive: a potential source of excess zinc resulting in copper deficiency myelopathy. Br Dent J 2011;210(11):523-5. PMID 21660014
12: da Silva-Junior FP, Lucato LT, Machado AA, Barbosa ER. Copper deficiency in Wilson's disease: an avoidable complication of treatment. Mov Disord 2011;26(13):2448-9. PMID 21956703
13: Ernst B, Thurnheer M, Schultes B. Copper deficiency after gastric bypass surgery. Obesity (Silver Spring) 2009;17(11):1980-1. PMID 19859058
14: Everett CM, Matharu M, Gawler J. Neuropathy progressing to myeloneuropathy 20 years after partial gastrectomy. Neurology 2006;66(9):1451. PMID 16682688
15: Foubert-Samier A, Kazadi A, Rouanet M, et al. Axonal sensory motor neuropathy in copper-deficient Wilson's disease. Muscle Nerve 2009;40(2):294-6. PMID 19609919
16: Francis Z, Book G, Litvin C, Kalivas B. The COVID-19 pandemic and zinc-induced copper deficiency: an important link. Am J Med 2022;S0002-9343(22)00244-3. PMID 35367442
17: Gabreyes AA, Abbasi HN, Forbes KP, McQuaker G, Duncan A, Morrison I. Hypocupremia associated cytopenia and myelopathy: a national retrospective review. Eur J Haematol 2013;90(1):1-9. PMID 23034053
18: Gletsu-Miller N, Broderius M, Frediani JK, et al. Incidence and prevalence of copper deficiency following roux-en-y gastric bypass surgery. Int J Obes 2012;36(3):328-35. PMID 21876546
19: Goodman BP, Bosch EP, Ross MA, Hoffman-Snyder C, Dodick DD, Smith BE. Clinical and electrodiagnostic findings in copper deficiency myeloneuropathy. J Neurol Neurosurg Psychiatry 2009a;(80):524-7. PMID 18495738
20: Goodman BP, Mistry DH, Pasha SF, Bosch PE. Copper deficiency myeloneuropathy due to occult celiac disease. Neurologist 2009b;15(6):355-6. PMID 19901719
21: Goodman JC. Neurological complications of bariatric surgery. Curr Neurol Neurosci Rep 2015;15(12):79. PMID 26493558
22: Greenberg SA, Briemberg HR. A neurological and hematological syndrome associated with zinc excess and copper deficiency. J Neurol 2004;251:111-4. PMID 14999501
23: Gregg XT, Reddy V, Prchal JT. Copper deficiency masquerading as myelodysplastic syndrome. Blood 2002;100(4):1493-5. PMID 12149237
24: Grossman JT, Ruiz S. Copper deficiency myeloneuropathy in autoimmune disease. Cureus 2021;13(7):e16591. PMID 34434682
25: Gupta HV, Jacob S, Archer RL, Gundogu B. A winged scapula and dropped wrist: an unusual manifestation of copper deficiency. Acta Neurol Belg 2016;116(2):235-7. PMID 26205794
26: Gurnari C, Rogers HJ. Copper Deficiency. N Engl J Med 2021;385(7):640. PMID 34358421
27: Gwathmey KG, Grogan J. Nutritional neuropathies. Muscle Nerve 2020;62(1):13-29. PMID 31837157
28: Halfdanarson T, Kumar N, Hogan WJ, Murray J. Copper deficiency in celiac disease. J Clin Gastroenterol 2009;43(2):162-4. PMID 18496230
29: Halfdanarson T, Kumar N, Li C-Y, Phyliky R, Hogan WJ. Hematological manifestations of copper deficiency. Eur J Hematol 2008;80(6):523-31. PMID 18284630
30: Hassan HA, Netchvolodoff C, Raufman JP. Zinc-induced copper deficiency in a coin swallower. Am J Gastroenterol 2000;95(10):2975-7. PMID 11051380
31: Hedera P, Fink JK, Bockenstedt PL, Brewer GJ. Myelopolyneuropathy and pancytopenia due to copper deficiency and high zinc levels of unknown origin: further support for existence of a new zinc overload syndrome. Arch Neurol 2003;60(9):1303-6. PMID 12975299
32: Hedera P, Peltier A, Fink JK, Wilcock S, London Z, Brewer GJ. Myelopolyneuropathy and pancytopenia due to copper deficiency and high zinc levels of unknown origin II. The denture cream is a primary source of excessive zinc. Neurotoxicology 2009;30(6):996-9. PMID 19732792
33: Henri-Bhargava A, Melmed C, Glikstein R, Schipper HM. Neurologic impairment due to vitamin E and copper deficiencies in celiac disease. Neurology 2008;71(11):860-1. PMID 18779515
34: Inaba M, Torii T, Shinoda K, Yamasaki R, Ohyagi Y, Kira J. [Peripheral neuropathy, myelopathy, cerebellar ataxia, and subclinical optic neuropathy associated with copper deficiency occurring 23 years after total gastrectomy]. Rinsho Shinkeigaku 2011;51(6):412-6. PMID 21735733
35: Ito H, Ogawa Y, Shimojo N, Kawano S. Copper and zinc deficiency in an alcoholic patient: a case report of a therapeutic dilemma. J Addict Dis 2022;40(4):583-7. PMID 35332856
36: Jaiser SR, Winston GP. Copper deficiency myelopathy. J Neurol 2010;257(6):869-81. PMID 20232210
37: Jamal R, Dihmis OW, Carroll LS, Pengas G. Hypocupraemia-induced anaemia, sensory ataxia and cognitive impairment secondary to zinc-containing dental adhesive. BMJ Case Rep 2021;14(7):e239375. PMID 34289999
38: Joshi S, McLarney M, Abramoff B. Copper deficiency related myelopathy 40 years following a jejunoileal bypass. Spinal Cord Ser Cases 2019;5:104. PMID 31871769
39: Juhasz-Pocsine K, Rudnicki SA, Archer RL, Harik SI. Neurologic complications of gastric bypass surgery for morbid obesity. Neurology 2007;68(21):1843-50. PMID 17515548
40: Karlikaya G, Kaya D. A new differential diagnosis for acquired demyelinating neuropathy: copper deficiency. Neurol India 2014;62(4):434-5. PMID 25237952
41: Kelkar P, Shereen C, Muley S. Response to oral supplementation in copper deficiency myeloneuropathy. J Clin Neuromuscul Dis 2008;10(1):1-3. PMID 18772693
42: Kennerson ML, Nicholson GA, Kaler SG, et al. Missense mutations in the copper transporter gene ATP7A cause X-linked distal hereditary motor neuropathy. Am J Hum Genet 2010;86(3):343-52. PMID 20170900
43: King D, Siau K, Senthil L, Kane KF, Cooper SC. Copper deficiency myelopathy after upper gastrointestinal surgery. Nutr Clin Pract 2018;33(4):515-9. PMID 28659010
44: Koizumi R, Kato H, Akagi A, et al. An autopsy case of copper deficiency myelopathy and selenium deficiency-associated central nervous system disorder after total parenteral nutrition. J Neurol Sci 2023;448:120636. PMID 36996722
45: Kumar G, Goyal MK, Lucchese S, Dhand U. Copper deficiency myelopathy can also involve the brain stem. AJNR Am J Neuroradiol 2011;32(1):E14-5. PMID 20947641
46: Kumar N. Copper deficiency myelopathy: human swayback. Mayo Clin Proc 2006;81(10):1371-84. PMID 17036563
47: Kumar N. Nutritional neuropathies. Neurology Clinics 2007;25(1):209-55. PMID 17324726
48: Kumar N. Metabolic and toxic myelopathies. Continuum. Spinal Cord, Root, and Plexus Disord 2008;14(3):91-115.
49: Kumar N, Ahlskog JE, Gross JB Jr. Acquired hypocupremia after gastric surgery. Clin Gastroenterol Hepatol 2004a;2(12):1074-9. PMID 15625652
50: Kumar N, Ahlskog JE, Klein CJ, Port JD. Imaging features of copper deficiency myelopathy: a study of 25 cases. Neuroradiol 2006;48(2):78-83. PMID 16261334
51: Kumar N, Butz JA, Burritt MF. Clinical significance of the laboratory determination of low serum copper in adults. Clin Chem Lab Med 2007;45(10):1402-10. PMID 17727313
52: Kumar N, Crum B, Petersen RC, Vernino SA, Ahlskog JE. Copper deficiency myelopathy. Arch Neurol 2004b;61(5):762-6. PMID 15148156
53: Kumar N, Elliott MA, Hoyer JD, Harper CM Jr, Ahlskog JE, Phyliky RL. “Myelodysplasia,” myeloneuropathy, and copper deficiency. Mayo Clin Proc 2005;80(7):943-6. PMID 16007901
54: Kumar N, Gross JB. Mutation in the ATP7A gene may not be responsible for hypocupremia in copper deficiency myelopathy. Postgrad Med J 2006;82(968):416. PMID 16754714
55: Kumar N, Gross JB Jr, Ahlskog JE. Myelopathy due to copper deficiency. Neurology 2003a;61(2):273-4. PMID 12874423
56: Kumar N, Gross JB Jr, Ahlskog JE. Copper deficiency myelopathy produces a clinical picture like subacute combined degeneration. Neurology 2004c;63(1):33-9. PMID 15249607
57: Kumar N, Knopman DS. SMON, clioquinol, and copper. Postgrad Med J 2005;81:227.
58: Kumar N, Low PA. Myeloneuropathy and anemia due to copper malabsorption. J Neurol 2004;251(6):747-9. PMID 15311353
59: Kumar N, McEvoy KM, Ahlskog JE. Myelopathy due to copper deficiency following gastrointestinal surgery. Arch Neurol 2003b;60(12):1782-5. PMID 14676057
60: Lang TF, Glynne-Jones R, Blake S, Taylor A, Kay JD. Iatrogenic copper deficiency following information and drugs obtained over the Internet. Ann Clin Biochem 2004;41(Pt 5):417-20. PMID 15333197
61: Lanska DJ, Remler B. Myelopathy among zinc-smelter workers in Upper Silesia during the late 19th century. Neurology 2014;82(13):1175-9. PMID 24688096
62: Lazarchick J. Update on anemia and neutropenia in copper deficiency. Curr Opin Hematol 2012;19(1):58-60. PMID 22080848
63: Lizaola-Mayo BC, Dickson RC, Lam-Himlin DM, Chascsa DM. Exogenous copper exposure causing clinical wilson disease in a patient with copper deficiency. BMC Gastroenterol 2021;21(1):278. PMID 34238237
64: Lozano Herrero J, Munoz Bertran E, Ortega Gonzalez I, Gomez Espin R, Lopez Espin MI. Myelopathy secondary to copper deficiency as a complication of treatment of Wilson's disease. Gastroenterol Hepatol 2012;35(10):704-7. PMID 22609346
65: Luo T, Zurko J, Astle J, Shah NN. Mimicking myelodysplastic syndrome: importance of differential diagnosis. Case Rep Hematol 2021;2021:9661765. PMID 34881068
66: Moon N, Aryan M, Westerveld D, Nathoo S, Glover S, Kamel AY. Clinical manifestations of copper deficiency: a case report and review of the literature. Nutr Clin Pract 2021;36(5):1080-5. PMID 33037701
67: Myint ZW, Oo TH, Thein KZ, Tun AM, Saeed H. Copper deficiency anemia: review article. Ann Hematol 2018;97(9):1527-34. PMID 29959467
68: Naismith RT, Shepherd JB, Weihl CC, Tutlam NT, Cross AH. Acute and bilateral blindness due to optic neuropathy associated with copper deficiency. Arch Neurol 2009;66(8):1025-7. PMID 19667226
69: Nakamura T, Nishi M, Rikitake M, et al. A case of subacute combined degeneration of the spinal cord due to folic acid and copper deficiency. Brain Dev 2019;41(1):111-5. PMID 30104084
70: Nations SP, Boyer PJ, Love LA, et al. Denture cream: an unusual source of excess zinc, leading to hypocupremia and neurological disease. Neurology 2008;71(9):639-43. PMID 18525032
71: Nishime K, Kondo M, Saito K, Miyawaki H, Nakagawa T. Zinc burden evokes copper deficiency in the hypoalbuminemic hemodialysis patients. Nutrients 2020;12(2):577. PMID 32102170
72: Page PS, Nazar RG, Park MC, James RF. Copper deficiency myelopathy in the setting of advanced degenerative cervical spondylosis. Br J Neurosurg 2016;30(4):453-5. PMID 26337459
73: Pantbalekundri N, Kumar S, Acharya S, Bedi G. Postpartum hypocupric myelopathy masquerading as acute transverse myelitis: a case report and literature review of a rare presentation. Cureus 2024;16:e52149. PMID 38344647
74: Pena I, Sarmiento J, Porras C, Cediel X, Camargo A. Myelopathy due to copper deficiency: a case series and review of the literature. Biomedica 2023;43:171-80. PMID 37433165
75: Penrith ML, Tustin RC, Thornton DJ, Burdett PD. Swayback in a blesbok (Damaliscus dorcas phillipsi) and a black wildebeest (Connochaetes gnou). J S Afr Vet Assoc 1996;67(2):93-6. PMID 8765071
76: Pineles SL, Wilson CA, Balcer LJ, Slater R, Galetta SL. Combined optic neuropathy and myelopathy secondary to copper deficiency. Surv Ophthalmol 2010;55(4):386-92. PMID 20451943
77: Plantone D, Renna R, Primiano G, Shukralla A, Koudriavtseva T. PPIs as possible risk factor for copper deficiency myelopathy. J Neurol Sci 2015;349(1-2):258-9. PMID 25598493
78: Prodan CI, Bottomley SS, Holland NR, Lind SE. Relapsing hypocupraemic myelopathy requiring high-dose oral copper replacement. J Neurol Neurosurg Psychiatry 2006;77(9):1092-3. PMID 16914761
79: Prodan CI, Holland NR. CNS demyelination from zinc toxicity. Neurology 2000;54(8):1705-6. PMID 10762525
80: Prodan CI, Holland NR, Wisdom PJ, Burstein SA, Bottomley SS. CNS demyelination associated with copper deficiency and hyperzincemia. Neurology 2002;59(9):1453-6. PMID 12427906
81: Rapoport Y, Lavin PJ. Nutritional optic neuropathy caused by copper deficiency after bariatric surgery. J Neuroophthalmol 2016;36(2):178-81. PMID 26828841
82: Rowin J, Lewis SL. Copper deficiency myeloneuropathy and pancytopenia secondary to overuse of zinc supplementation. J Neurol Neurosurg Psychiatry 2005;76(5):750-1. PMID 15834043
83: Schaumburg H, Herskovitz S. Copper deficiency myeloneuropathy: a clue to clioquinol-induced subacute myelo-optic neuropathy. Neurology 2008;71:622-3. PMID 18725588
84: Schleper B, Stuerenburg HJ. Copper deficiency-associated myelopathy in a 46-year-old woman. J Neurol 2001;248(8):705-6. PMID 11569901
85: Shook SJ, Tsao B, Shields RJ. Acquired copper deficiency myelopathy with autonomic neuropathy. Muscle Nerve 2006;34:524.
86: Sorenson EJ. Copper deficiency misdiagnosed as postpolio syndrome. J Clin Neuromuscul Dis 2006;8(2):70-4.
87: Spain RI, Leist TP, De Sousa EA. When metals compete: a case of copper-deficiency myeloneuropathy and anemia. Nat Clin Pract Neurol 2009;5(2):106-11. PMID 19194390
88: Spinazzi M, De Lazzari F, Tavolato B, Angelini C, Manara R, Armani M. Myelo-optico-neuropathy in copper deficiency occurring after partial gastrectomy. Do small bowel bacterial overgrowth syndrome and occult zinc ingestion tip the balance. J Neurol 2007;254(8):1012-7. PMID 17415508
89: Taylor G, Jeyarajan E. Acute copper deficiency myelopathy after single-anastomosis gastric bypass. Oxf Med Case Reports 2023;2023(12):omad138. PMID 38145264
90: Taylor SW, Laughlin RS, Kumar N, et al. Clinical, physiological and pathological characterisation of the sensory predominant peripheral neuropathy in copper deficiency. J Neurol Neurosurg Psychiatry 2017;88(10):839-45. PMID 28780535
91: Thackeray EW, Sanderson SO, Fox JC, Kumar N. Hepatic iron overload or cirrhosis may occur in acquired copper deficiency and is likely mediated by hypoceruloplasminemia. J Clin Gastroenterol 2011;45(2):153-8. PMID 20502350
92: Turnlund JR. Copper. In: Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ, editors. Modern nutrition in health and disease. 10th ed. Baltimore: Lippincott Williams and Wilkins, 2006:286-99.
93: Ueda M, Katsuse K, Kakumoto T, et al. Copper deficiency in Wilson's disease with a normal zinc value. Internal Med 2023;62(7):1073-6. PMID 36047117
94: Valentine JS, Gralla EB. Delivering copper inside yeast and human cells. Science 1997;278(5339):817-8. PMID 9381192
95: Verma R, Praharaj HN, Khanna VK, Garg RK, Singh MK, Malhotra HS. Study of micronutrients (copper, zinc and vitamin B12) in posterolateral myelopathies. J Neurol Sci 2013;329(1-2):11-6. PMID 23562297
96: Videt-Gibou D, Belliard S, Rivalan J, Menard D, Edan G. [Acquired copper deficiency myelopathy]. Rev Neurol (Paris) 2010;166(6-7):639-43. PMID 20466396
97: Weihl CC, Lopate G. Motor neuron disease associated with copper deficiency. Muscle Nerve 2006;34:789-93. PMID 16929546
98: Willis MS, Monaghan SA, Miller ML, et al. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Am J Clin Pathol 2005;123(1):125-31. PMID 15762288
99: Winston GP, Jaiser SR. Copper deficiency myelopathy and subacute combined degeneration of the cord--why is the phenotype so similar. Med Hypotheses 2008;71(2):229-36. PMID 18472229
100: Wu LM, Ekladious A, Wheeler L, Mohamad AA. Wilson disease: copper deficiency and iatrogenic neurological complications with zinc therapy. Intern Med J 2020;50(1):121-3. PMID 31943611
101: Yaldizli O, Johansson U, Gizewski ER, Mschke M. Copper deficiency myelopathy induced by parenteral zinc supplementation during chronic hemodialysis. J Neurol 2006;253(11):1507-9. PMID 16972121
102: Yarandi SS, Griffith DP, Sharma R, Mohan A, Zhao VM, Ziegler TR. Optic neuropathy, myelopathy, anemia, and neutropenia caused by acquired copper deficiency after gastric bypass surgery. J Clin Gastroenterol 2014;48(10):862-5. PMID 24583748
103: Zara G, Grassivaro F, Brocadello F, Manara R, Pesenti FF. Case of sensory ataxic ganglionopathy-myelopathy in copper deficiency. J Neurol Sci 2009;277(1-2):184-6. PMID 19022461
104: Zittel S, Ufer F, Gerloff C, Munchau A, Rosenkranz M. Severe myelopathy after denture cream use--is copper deficiency or excess zinc the cause? Clin Neurol Neurosurg 2014;121:17-8. PMID 24793467

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Neeraj Kumar MD

Dr. Kumar of the Mayo Clinic and the Mayo College of Medicine has no relevant financial relationships to disclose.
See Profile

Editor

Louis H Weimer MD

Dr. Weimer of Columbia University has no relevant financial relationships to disclose.
See Profile

Patient Profile

Age range of presentation: 1 month to 65+ years
Sex preponderance: female>male, >3.6:1
Heredity: none
Population groups selectively affected: Bariatric surgery

Malabsorption

Excess zinc ingestion
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Other diseases of the spinal cord: G95

Disorders of copper metabolism: E83.0
ICD-11: Copper deficiency anaemia: 3A03.3

Copper deficiency: 5B5K.6

Other specified disorders of copper metabolism: 5C64.0Y

Other specified white matter disorders due to nutritional deficiency: 8A45.3Y

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Copper deficiency myeloneuropathy

Associated Disorders

malabsorption
zinc toxicity

Differential Diagnosis

vitamin B12 deficiency
nitrous oxide toxicity
vitamin E deficiency
folate deficiency
HIV myelopathy

Also Relevant

Menkes disease and other ATP7A-related disorders
Nutrition-related peripheral neuropathies
Toxic and nutritional deficiency optic neuropathies
Vitamin B12 deficiency

Clinical Categories

Web References

Clinical Trials

FDA: Copper Deficiency

Copper deficiency myeloneuropathy …

Copper deficiency myeloneuropathy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

References

Contributors

Author

Editor

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Familial dysautonomia

Neurogenetics and genetic and genomic testing

Acute traumatic spinal cord injury

Tumors of the skull base

Toxic and nutritional deficiency optic neuropathies

Third nerve palsy

Nystagmus

Copper deficiency myeloneuropathy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

References

Contributors

Author

Editor

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Familial dysautonomia

Neurogenetics and genetic and genomic testing

Acute traumatic spinal cord injury

Tumors of the skull base

Toxic and nutritional deficiency optic neuropathies

Third nerve palsy

Nystagmus

This is an article preview.
Start a Free Account
to access the full version.